Natco Pharma unveils additional strengths of generic Revlimid in U.S.

With the launch, the companies have made available all the strengths of lenalidomide in the U.S. market,

Published - March 10, 2023 12:00 pm IST - HYDERABAD

A bottle of Revlimid seen at a store in Utah. File photo

A bottle of Revlimid seen at a store in Utah. File photo | Photo Credit: Reuters

Natco Pharma has launched its generic version of Celgene Corporation’s cancer drug Revlimid (lenalidomide capsules) in additional strengths in the United States.

The 2.5 mg and 20 mg strengths of the prescription medicine used in adults for the treatment of multiple myeloma has been launched through its marketing partner Teva Pharmaceuticals, which is a U.S. affiliate of Teva Pharmaceutical Industries.

With the launch, the companies have made available all the strengths of lenalidomide in the U.S. market, Natco said in a release on March 10.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.